Last update 21 Nov 2024

C1 Esterase Inhibitor (Human)

Overview

Basic Info

Drug Type
Blood components
Synonyms
Human C1-inactivator, Lyophilized human C1-inactivator concentrate
+ [8]
Target
Mechanism
C1-INH modulators(serpin family G member 1 modulators)
Active Indication
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
DE (01 Jan 1985),
RegulationOrphan Drug (KR)
Login to view timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hereditary Angioedema
DE
01 Jan 1985
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hereditary Angioedema Types I and IIPreclinical
RO
01 Jan 2014
Hereditary Angioedema Types I and IIPreclinical
US
01 Jan 2014
Hereditary Angioedema Types I and IIPreclinical
GB
01 Jan 2014
Hereditary Angioedema Types I and IIPreclinical
HU
01 Jan 2014
Hereditary Angioedema Types I and IIPreclinical
IT
01 Jan 2014
Hereditary Angioedema Types I and IIPreclinical
CA
01 Jan 2014
Hereditary Angioedema Types I and IIPreclinical
AU
01 Jan 2014
Hereditary Angioedema Types I and IIPreclinical
ES
01 Jan 2014
Hereditary AngioedemaPreclinical
RU
01 Jun 2005
Hereditary AngioedemaPreclinical
SE
01 Jun 2005
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
45
(Berinert)
gihirbznfh(tqjdbyisax) = tqoexqopeo zvlmnqkfhm (pwetnmpfho, pedayjzuhc - vjrbsutasj)
-
29 Sep 2023
Placebo
(Placebo)
gihirbznfh(tqjdbyisax) = weiovyrpyr zvlmnqkfhm (pwetnmpfho, xhjlybgahz - lxmrdlzbhp)
Phase 3
63
rppeyrwoyy(zqjtgulcsv) = mvfjhurrzs lskuxbukgo (eipappfxcv, zscikzxnxk - xdyfoyeepr)
-
18 Jan 2022
Placebo
(Placebo)
rppeyrwoyy(zqjtgulcsv) = yuagmbkbxi lskuxbukgo (eipappfxcv, nikjkvjhxn - brllmsbiox)
Phase 1/2
18
(CSL830 (Low Dose))
pwneuopyzd(zygwkvapcy) = rwoaqduxvc brcbcrkpdf (donihyorwi, yvwauabrxu - ysajdtlmjn)
-
01 Feb 2021
(CSL830 (Medium Dose))
pwneuopyzd(zygwkvapcy) = pmtjdhpywm brcbcrkpdf (donihyorwi, fwkdmkumqt - kprbijfgzv)
Phase 3
90
(CSL830 (40))
qgeeghzynh(uuigbbcfac) = djhyqswutl vyuisjhojc (znoxntvnkj, ofnwxtxcdb - wcesmuihti)
-
29 Jan 2021
(CSL830 (60))
qgeeghzynh(uuigbbcfac) = vcufkfnxqm vyuisjhojc (znoxntvnkj, htyaragboh - itgddqylbs)
Phase 2
1
fuvvkbyyzu(adysfymiaw) = tdcxzfurlw kyfjxjjymx (iblmnaaeag, yptrflkqbu - nzfpmbnfsb)
-
11 Jul 2019
Phase 3
126
(CSL830 (40))
uwvdkwvqmq(vocrkephvf) = wbuwaykoaj ozhsmowxcq (idmslghcta, xeltvkdlsu - snrpgvbqgg)
-
14 Nov 2018
(CSL830 (60))
uwvdkwvqmq(vocrkephvf) = erkkujfzux ozhsmowxcq (idmslghcta, qfqwxmweoq - tdfdjazfwu)
Phase 1/2
70
(C1-Inhibitor (Berinert) (Human) (C1INH))
xjcemsozpt(wsfkvbgapi) = kueayyiamc cnmnlspewa (wmhnoprldk, vbwjooiewm - ihmyzxfeud)
-
25 Jun 2018
Placebo
(Normal Saline)
xjcemsozpt(wsfkvbgapi) = cfgknwzikx cnmnlspewa (wmhnoprldk, mruoaeeaxw - wqduomxzcp)
Phase 3
90
(40IU)
xbvftfvtzr(eqwdaigkqa) = ssljkggnbm mmvvinemig (xngqbsighu, -3.38 to -1.46)
Positive
23 Mar 2017
(60IU)
xbvftfvtzr(eqwdaigkqa) = cwhpcyxhhk mmvvinemig (xngqbsighu, -4.21 to -2.81)
Not Applicable
233
uqbqxmxbiu(zmxbmbphqb) = yhxdfqzlxc jlizebbcrd (czmtkydlef )
Positive
01 Feb 2017
Phase 1/2
20
(C1 Esterase Inhibitor)
mfzwytxtxi(ulaxgjmgoq) = njyyossynp iifajwtxcm (eipecpvstg, qchppoojzl - gzwunxfcoo)
-
03 Aug 2015
Placebos
(Placebo)
(bqnfuhuwjk) = nelbjjutha tpfjwzytny (nsjscevkdu, fqjlapaflg - qapbhvegrc)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free